A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

Exclusion Criteria

• •Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or off-label use of a drug or device other than the study drug used in this study, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• •Have known allergies/intolerance to LY2216684, sertraline, or related compounds.
• •Are persons who previously completed or discontinued from this study, or any other study investigating LY2216684 within 6 months prior to screening.
• •Have a clinically significant abnormality in the 12-lead electrocardiogram (ECG) as determined by the investigator.
• •Have significant history of or current cardiovascular (including dysrhythmias), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
• •Have a history of seizure disorders.
• •Have a history or presence of the signs and/or symptoms of hyponatremia.
• •Have a history or presence of the signs and/or symptoms of hyperthyroidism as determined by an abnormal thyroid stimulating hormone (TSH) at screening.
• •Have a history or presence of the signs and/or symptoms of urinary retention or benign prostatic hypertrophy.
• •Show evidence of significant active neuropsychiatric disease or a history of suicidal thoughts or suicide attempt.
• •Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
• •Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
• •Show evidence of hepatitis C and/or positive hepatitis C antibody.
• •Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
• •Are women with a positive pregnancy test or women who are lactating.
• •Intend to use over-the-counter or prescription medication within 14 days prior to dosing unless deemed acceptable by the investigator and sponsor's medical monitor.
• •Have donated blood of more than 500 milliliters (mL) within 4 weeks prior to screening.
• •Have an average weekly alcohol intake that exceeds 14 units per week or are unwilling to stop alcohol consumption 48 hours prior to check-in until the completion of the study (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
• •Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any participants unwilling to adhere to study caffeine restrictions.
• •Have used any tobacco-containing or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
• •Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
• •Have a documented or suspected history of glaucoma.
• •Participants determined to be unsuitable by the investigator for any reason.